Preparation of porphyrin and phthalocyanine organometallic compounds for the treatment of cancer

The present invention relates to novel organometallic compds. for use as a medicine, in particular in photodynamic therapy against various diseases, such as cancer. The compds. comprise a central porphyrin or phthalocyanine backbone to which ligand linkers coordinated to at least one transition metal are attached. Eta-5 or eta-6 arenes further bind to the transition metal. According to a preferred embodiment, the compd. is a tetranuclear Ruthenium (+II) complex. Thus, reaction of [Ru(η6-C6H6)(μ-Cl)Cl]2 with 5,10,15,20-(pyrid-4-yl)porphyrin (TPP) in refluxing MeOH gave 56% title compd., [Ru4(η6-C6H6)4(TPP)Cl8].


  • There is no available fulltext. Please contact the lab or the authors.

Related material